Fast discharge after heart attack treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates whether a fast discharge strategy, allowing patients to leave the hospital 24 hours after treatment for acute myocardial infarction, is as safe as the standard discharge time of 72 hours. It is a randomized, multicenter trial that focuses on patients who have undergone invasive management for their heart condition. The primary goal is to assess the risk of major adverse cardiovascular events within 12 months following discharge. By comparing these two discharge strategies, the study aims to determine if quicker discharge can be safely implemented without increasing risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
* Age ≥ 18 years at time of consent
* Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-interventional TIMI 3 flow
* Ability to understand and willingness to sign and date written informed consent

Exclusion Criteria:

* Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
* PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage and arterial dissection/occlusion or emboli)
* Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree atrioventricular block) after PCI
* Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
* Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema)
* Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
* Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3
* Pregnancy
* Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge
* Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team

Where it's running

• Hospital Wiener Neustadt
  Wiener Neustadt, Lower Austria, Austria Recruiting
• Paracelsus Medical University Salzburg
  Salzburg, State of Salzburg, Austria Recruiting
• Medical University of Graz
  Graz, Styria, Austria Recruiting
• Medical University of Innsbruck
  Innsbruck, Tyrol, Austria Recruiting
• University Teaching Hospital Wels-Grieskirchen
  Wels, Upper Austria, Austria Recruiting
• Academic Teaching Hospital Feldkirch
  Feldkirch, Vorarlberg, Austria Recruiting

Study contacts

• Principal investigator: Martin Reindl, MD, PhD — Medical University Innsbruck
• Study coordinator: Martin Reindl, MD, PhD
• Email: martin.reindl@tirol-kliniken.at
• Phone: +43 512 504 25665

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can 1-Hz rTMS help with heart rhythm and inflammation after a heart attack?

  This trial tests whether daily 1-Hz repetitive transcranial magnetic stimulation can improve heart rate variability and reduce inflammation in people who have had an acute myocardial infarction, compared with a sham procedure.

  Recruiting Beijing Hospital · Beijing, Beijing Municipality · NCT07842770

• Trends and risk factors for adverse events after primary PCI in AMI patients over 20 years

  This study looks at real-world AMI patients who had a primary PCI to see how often serious events happen during a 2-year follow-up and what factors predict them.

  Recruiting Shanghai Zhongshan Hospital · Shanghai · NCT07833995

• SPIKE FLOW endocardial pacing lead safety and performance study

  This study tests whether the SPIKE FLOW temporary endocardial pacing lead is safe and effective in adults needing temporary pacing during heart-related conditions.

  Recruiting at 2 sites FIAB SpA · Acquaviva delle Fonti, Bari and 2 other locations · NCT07820072

• Predict Arrhythmia Risk with Intelligent Software

  Researchers are testing AI-powered predictions to see if clinicians can spot patients at risk for dangerous heart rhythms using bedside ECG data.

  Recruiting Catharina Ziekenhuis Eindhoven · Eindhoven, North Brabant · NCT07792694

• Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care

  In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.

  Recruiting Leipzig Heart Science gGmbH · Leipzig, Saxony · NCT07762560

• BRIDGE: Embedding consumer mHealth tools into cardiac rehab

  This study tests whether adding a mobile health tool to standard center-based cardiac rehab helps heart patients stay active and follow healthy habits.

  Recruiting University of Illinois Chicago · Chicago, Illinois · NCT07741396

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.